28 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
A and B virus infection ... A virus (HAV) infection ... #OIs #HIVAIDS # ... IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
A and B virus infection ... A virus (HAV) infection ... #OIs #HIVAIDS # ... IDSA #management ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Penicillium marneffei Infections ... Treating Acute Infection ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
Drug of choice for systemic anaphylaxis - High yield pharmacology notes
#pharmacology #management #algorithm #criticalcare
anaphylaxis - High yield pharmacology ... notes #pharmacology ... #management #algorithm ... #criticalcare
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Infection in HIV-AIDS ... Infection General ... Management Considerations ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Algorithm for the Management of Purulent skin and soft tissue infections (SSTIs). 
Mild infection: for
IDSA Algorithm for ... the Management ... 12 000 or <400 cells ... #SSTIs #Algorithm ... #Management #skin
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Papillomavirus Infections ... of mode of HIV infection ... Episode of HPV Infection ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Bacterial Enteric Infections ... Clostridium difficile Infection ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
CD4 count <200 cells ... Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Prevention #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology